Advanced Esophageal Squamous Cell Cancer Clinical Trial
Official title:
A Phase II Prospective, Open-label Clinical Trial of Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Patients With Locally Advanced Esophageal Squamous Cell Cancer
Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment
option for locally advanced esophageal squamous cell cancer (ESCC). However, only 20% to 40%
of patients can achieve pathologic complete response (pCR) after neoadjuvant CRT with
favorable prognosis and about 10% of patients have disease progression after
chemoradiotherapy. How to improve the the efficacy of neoadjuvant therapy is an important
clinical problem to be solved.
Immunotherapy targeting the PD-1/PD-L1 checkpoints has demonstrated promising activity in
advanced EC especially in ESCC. In Keynote181 study, for patients with metastatic esophageal
squamous cell carcinoma, regardless of PD-L1 expression, pembrolizumab significantly improved
overall survival compared with chemotherapy. However, the efficacy and safety of
immunotherapy therapy in surgery-based multidisciplinary treatment of local advanced
esophageal cancer still need a lot of clinical studies to further confirm.
The aim of this study was to evaluate the efficacy and safety of the neoadjuvant
chemoradiotherapy combined with perioperative toripalimab in patients with locally advanced
esophageal squamous cell cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03732508 -
SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04797507 -
SHR-1210 in Combination With Anlotinib in Patients With Advanced or Metastatic Esophageal Squamous Cell Cancer
|
Phase 2 | |
| Recruiting |
NCT05323890 -
Tislelizumab Combined With Neoadjuvant Radiotherapy and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma.
|
Phase 2 |